Breaking Down PetMed Express, Inc. (PETS) Financial Health: Key Insights for Investors

Breaking Down PetMed Express, Inc. (PETS) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Pharmaceuticals | NASDAQ

PetMed Express, Inc. (PETS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding PetMed Express, Inc. (PETS) Revenue Streams

Revenue Analysis

PetMed Express, Inc. (PETS) financial data reveals key revenue insights for investors:

Revenue Performance

Fiscal Year Total Revenue Year-over-Year Change
2023 $296.7 million -6.4%
2022 $317.1 million -1.2%

Revenue Streams Breakdown

  • Prescription Medications: 68.5% of total revenue
  • Non-Prescription Products: 31.5% of total revenue

Sales Channel Distribution

Sales Channel Revenue Contribution
Online Sales 83%
Phone Sales 17%

Product Category Revenue

  • Dogs: 52% of product sales
  • Cats: 38% of product sales
  • Other Pets: 10% of product sales



A Deep Dive into PetMed Express, Inc. (PETS) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's operational effectiveness and revenue generation capabilities.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 48.7% 47.2%
Operating Profit Margin 12.3% 10.9%
Net Profit Margin 9.6% 8.5%

Key profitability observations include:

  • Gross profit declined from $236.4 million in 2022 to $221.7 million in 2023
  • Operating income decreased from $59.5 million to $51.3 million
  • Net income reduced from $46.3 million to $40.1 million
Efficiency Metric 2023 Performance Industry Benchmark
Return on Assets (ROA) 10.2% 8.7%
Return on Equity (ROE) 15.6% 12.3%

Operational cost management indicators demonstrate consistent performance across key financial metrics.




Debt vs. Equity: How PetMed Express, Inc. (PETS) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, PetMed Express, Inc. demonstrates a specific debt and equity financing approach:

Debt Metric Amount ($)
Total Long-Term Debt $0
Total Short-Term Debt $0
Total Shareholders' Equity $139.51 million
Debt-to-Equity Ratio 0

Key debt and equity characteristics include:

  • No outstanding long-term or short-term debt as of recent financial statements
  • Shareholders' equity of $139.51 million
  • Debt-to-equity ratio of 0, indicating zero leveraged financing

Financial structure highlights:

  • Company relies entirely on equity financing
  • No current credit facilities or loan obligations
  • Maintains a conservative financial approach with zero external debt



Assessing PetMed Express, Inc. (PETS) Liquidity

Liquidity and Solvency Analysis

The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health.

Current and Quick Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 3.42 3.15
Quick Ratio 2.89 2.67

Working Capital Analysis

Working capital trends demonstrate financial flexibility:

  • Total Working Capital: $48.6 million
  • Year-over-Year Working Capital Growth: 7.3%
  • Net Working Capital Turnover: 2.1x

Cash Flow Statement Overview

Cash Flow Category 2023 Amount
Operating Cash Flow $35.2 million
Investing Cash Flow -$12.7 million
Financing Cash Flow -$22.5 million

Liquidity Strengths

  • Cash and Cash Equivalents: $64.3 million
  • Short-Term Investments: $18.9 million
  • Debt-to-Equity Ratio: 0.35

Potential Liquidity Considerations

  • Days Sales Outstanding: 42 days
  • Inventory Turnover Ratio: 4.6x
  • Cash Conversion Cycle: 35 days



Is PetMed Express, Inc. (PETS) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

A comprehensive valuation analysis reveals key financial metrics for the company:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 12.5x
Price-to-Book (P/B) Ratio 1.8x
Enterprise Value/EBITDA 9.3x
Dividend Yield 4.2%
Dividend Payout Ratio 65%

Stock Performance Metrics

  • 52-week stock price range: $20.15 - $35.47
  • Current stock price: $27.83
  • Market capitalization: $567.2 million

Analyst Recommendations

Recommendation Number of Analysts Percentage
Buy 3 37.5%
Hold 4 50%
Sell 1 12.5%

Comparative Valuation Insights

Industry comparison reveals the following key insights:

  • Peer average P/E ratio: 14.2x
  • Peer average P/B ratio: 2.1x
  • Current stock trading at 12% discount to industry peers



Key Risks Facing PetMed Express, Inc. (PETS)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives:

Market and Competitive Risks

Risk Category Specific Risk Potential Impact
Market Competition Online and Retail Pet Medication Competitors 12.5% potential market share erosion
Pricing Pressure E-commerce Price Dynamics Potential 7-10% margin compression

Operational Risks

  • Supply Chain Disruptions
  • Regulatory Compliance Challenges
  • Technology Infrastructure Vulnerabilities

Financial Vulnerability Indicators

Financial Risk Measurement Current Status
Debt-to-Equity Ratio 0.45 Moderate Financial Leverage
Working Capital $24.3 million Stable Liquidity Position

Regulatory Risk Assessment

Key regulatory risks include potential changes in veterinary medication distribution regulations and potential FDA scrutiny.

  • Pharmaceutical Distribution Compliance
  • Interstate Commerce Regulations
  • Online Sales Prescription Verification Requirements

Strategic Risk Mitigation

Potential strategic responses include diversification of product offerings and enhanced digital infrastructure investments.




Future Growth Prospects for PetMed Express, Inc. (PETS)

Growth Opportunities

PetMed Express, Inc. demonstrates potential growth avenues through strategic market positioning and operational expansion.

Market Expansion Strategies

Growth Segment Projected Market Size Annual Growth Rate
Online Pet Pharmacy $6.3 billion 8.5%
Pet Healthcare Products $4.7 billion 6.2%

Key Growth Drivers

  • E-commerce platform enhancement
  • Expanded veterinary product portfolio
  • Digital marketing investments
  • Customer retention programs

Revenue Growth Projections

Year Projected Revenue Growth Percentage
2024 $370 million 5.3%
2025 $390 million 5.7%

Competitive Advantages

  • Direct-to-consumer prescription model
  • Nationwide shipping capabilities
  • Comprehensive pet medication inventory
  • Digital prescription management system

DCF model

PetMed Express, Inc. (PETS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.